Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9768854 | 0.94 | NAAA (0.32) | ALDH1A1 | |
| SCHEMBL29263277 | 0.92 | NAAA (0.35) | ALDH1A1 | |
| SCHEMBL10044939 | 0.86 | EGFR (0.33) | — | |
| SCHEMBL14357391 | 0.84 | ALDH1A1 (0.33) | ALDH1A1ATM | |
| SCHEMBL25613184 | 0.83 | ALDH1A1 (0.30) | ALDH1A1 | |
| SCHEMBL16692038 | 0.83 | CYP4F2 (0.31) | ALDH1A1 | |
| SCHEMBL14296190 | 0.83 | GRIN2D (0.39) | ALDH1A1 | |
| SCHEMBL14296188 | 0.83 | GRIN2D (0.39) | ALDH1A1 | |
| SCHEMBL26527857 | 0.83 | ALDH1A1 (0.30) | ALDH1A1 | |
| SCHEMBL13227577 | 0.82 | ALDH1A1 (0.33) | ALDH1A1ATM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 33 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11786605-B2 | Site specific antibody-drug conjugates with peptide-containing linkers | MERSANA THERAPEUTICS, INC. (US) | 2023-10-17 | — | — | US | disclosed |
| US-20230183326-A1 | PROTEIN-POLYMER-DRUG CONJUGATES | ASANA BIOSCIENCES, LLC | 2023-06-15 | — | — | US | disclosed |
| US-20180200273-A1 | Silanol Based Therapeutic Payloads | BLINKBIO INC (US) | 2018-07-19 | — | — | US | disclosed |
| US-20180154018-A1 | PEPTIDE-CONTAINING LINKERS FOR ANTIBODY-DRUG CONJUGATES | MERSANA THERAPEUTICS, INC. | 2018-06-07 | — | — | US | disclosed |
| US-20180140716-A1 | PROTEIN-POLYMER-DRUG CONJUGATES | MERSANA THERAPEUTICS, INC. | 2018-05-24 | — | — | US | disclosed |
| US-9943609-B2 | Protein-polymer-drug conjugates | MERSANA THERAPEUTICS, INC. (US) | 2018-04-17 | — | — | US | disclosed |
| US-9872918-B2 | Hydroxyl-polymer-drug-protein conjugates | MERSANA THERAPEUTICS, INC. (US) | 2018-01-23 | — | — | US | disclosed |
| US-9849191-B2 | Protein-polymer-drug conjugates | MERSANA THERAPEUTICS, INC. (US) | 2017-12-26 | — | — | US | disclosed |
| US-20170348424-A1 | PROTEIN-POLYMER-DRUG CONJUGATES | MERSANA THERAPEUTICS, INC. | 2017-12-07 | — | — | US | disclosed |
| US-9808528-B2 | Protein-polymer-drug conjugates and methods of using same | MERSANA THERAPEUTICS, INC. (US) | 2017-11-07 | — | — | US | disclosed |
| US-20140315790-A1 | AMINOTHIAZOLES AND THEIR USES | BUSHELL SIMON (US) | 2014-10-23 | — | — | US | disclosed |
| US-8821850-B2 | Protein-polymer-drug conjugates | MERSANA THERAPEUTICS, INC. (US) | 2014-09-02 | — | — | US | disclosed |
| US-8815226-B2 | Protein-polymer-drug conjugates | MERSANA THERAPEUTICS, INC. (US) | 2014-08-26 | — | — | US | disclosed |
| US-8808679-B2 | Auristatin compounds and conjugates thereof | MERSANA THERAPEUTICS, INC. (US) | 2014-08-19 | — | — | US | disclosed |
| US-20140134127-A1 | Protein-Polymer-Drug Conjugates | MERSANA THERAPEUTICS, INC. (US) | 2014-05-15 | — | — | US | disclosed |
| US-20140017265-A1 | Terminally Modified Polymers and Conjugates Thereof | MERSANA THERAPEUTICS, INC. | 2014-01-16 | — | — | US | disclosed |
| US-20130309192-A1 | Auristatin Compounds and Conjugates Thereof | MERSANA THERAPEUTICS, INC. (US) | 2013-11-21 | — | — | US | disclosed |
| US-20130101546-A1 | Protein-Polymer-Drug Conjugates | MERSANA THERAPEUTICS, INC. (US) | 2013-04-25 | — | — | US | disclosed |
| US-8426428-B2 | EGFR kinase knockdown via electrophilically enhanced inhibitors | PRINCIPIA BIOPHARMA, INC. (US) | 2013-04-23 | — | — | US | disclosed |
| US-20120321583-A1 | Protein-Polymer-Drug Conjugates | MERSANA THERAPEUTICS, INC. (US) | 2012-12-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (12 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170348424-A1 | PROTEIN-POLYMER-DRUG CONJUGATES | PBRM1, CLTB, BRAP | ALDH1A1 3556/4885ATM 3204/4885 |
| US-20140134127-A1 | Protein-Polymer-Drug Conjugates | PBRM1, CLTB, BRAP | ALDH1A1 3556/4885ATM 3204/4885 |
| US-20230183326-A1 | PROTEIN-POLYMER-DRUG CONJUGATES | PBRM1, STAMBP, TSPO | ALDH1A1 3681/4885ATM 3192/4885 |
| US-20180140716-A1 | PROTEIN-POLYMER-DRUG CONJUGATES | PBRM1, STAMBP, TSPO | ALDH1A1 3681/4885ATM 3192/4885 |
| US-20140017265-A1 | Terminally Modified Polymers and Conjugates Thereof | MALT1, ALG1, PRMT3 | ALDH1A1 2397/4885ATM 2935/4885 |
| US-20180200273-A1 | Silanol Based Therapeutic Payloads | CD47, CD4, BST2 | ALDH1A1 1176/4885ATM 3504/4885 |
| US-11786605-B2 | Site specific antibody-drug conjugates with peptide-containing linkers | CD2BP2, DNPEP, LNPEP | ALDH1A1 2981/4885ATM 3683/4885 |
| US-20120321583-A1 | Protein-Polymer-Drug Conjugates | PBRM1, CLTB, BRAP | ALDH1A1 3556/4885ATM 3204/4885 |
| US-20140315790-A1 | AMINOTHIAZOLES AND THEIR USES | ABAT, AADAT, GOT2 | ALDH1A1 353/4885ATM 616/4885 |
| US-20180154018-A1 | PEPTIDE-CONTAINING LINKERS FOR ANTIBODY-DRUG CONJUGATES | CD2BP2, DNPEP, LNPEP | ALDH1A1 3141/4885ATM 3138/4885 |
| US-20130101546-A1 | Protein-Polymer-Drug Conjugates | PBRM1, CLTB, BRAP | ALDH1A1 3507/4885ATM 3169/4885 |
| US-20130309192-A1 | Auristatin Compounds and Conjugates Thereof | PBRM1, AURKB, PEBP1 | ALDH1A1 2815/4885ATM 1728/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.